Addition of the QW Modifier to Healthcare Common Procedure Coding System (HCPCS) Codes 0240U, 0241U, and 87637

MLN Matters Number: MM12318
Related Change Request (CR) Number: 12318
Related CR Release Date: June 11, 2021
Effective Date: October 6, 2020
Related CR Transmittal Number: R10827OTN
Implementation Date: July 6, 2021

Provider Types Affected

This MLN Matters Article is for physicians, other providers, and clinical diagnostic laboratories that submit claims to Medicare Administrative Contractors (MACs) for laboratory services for Medicare patients.

Provider Action Needed

This Article tells you of the addition of the QW modifier to certain CMS HCPCS codes (0240U, 0241U, and 87637).

Background

CMS included the following HCPCS codes in CR 12080 (see related Article MM12080):

- 0240U - [Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected]
- 0241U [Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected]
- 87637 [Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique]

The effective date of these 3 codes is October 6, 2020.
On February 4, 2020, the HHS Secretary determined there is a public health emergency due to the virus that causes Coronavirus disease 2019. Currently, there isn’t an FDA approved or cleared test to diagnose or detect Coronavirus disease 2019. The FDA has issued several In Vitro Diagnostic Emergency Use Authorizations (EUAs) for SAR-CoV-2 and Coronavirus disease 2019.

The FDA has issued at least 1 EUA for infectious agent detection by nucleic acid for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), influenza virus types A and B, and respiratory syncytial virus using multiplex and amplified probe technique. The FDA authorized the test for use at the point of care setting, that is, in patient care settings operating under a Clinical Laboratory Improvement Amendments (CLIA) Certificate of Waiver. The HCPCS codes 0240U, 0241U and 87637 describe the testing you perform with this EUA.

When the FDA authorizes tests for use at the point of care (including SARS-CoV-2 point of care test systems) under an EUA, such tests are deemed to be CLIA waived tests. Accordingly, for the duration of the emergency declaration, you can perform such tests in a patient care setting that qualified to have the test performed there by operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

For Medicare to recognize these tests you perform under a CLIA certificate of waiver or a CLIA certificate for provider-performed microscopy procedures, you must add the modifier QW to HCPCS codes 0240U, 0241U, and 87637.

More Information

We issued CR 12318 to your MAC as the official instruction for this change.

For more information, contact your MAC.

Document History

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 11, 2021</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

Disclaimer: Paid for by the Department of Health & Human Services. This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2020 American Medical Association. All rights reserved.

Copyright © 2013-2021, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association.
license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@healthforum.com.

The American Hospital Association (the “AHA”) has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.